Compare MINISO Group Holding Ltd (MNSO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs Sana Biotechnology Inc — how do they compare? MINISO Group Holding Ltd trades at $9.6 (market cap $2.65B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: MINISO Group Holding Ltd is far larger — about 3.2× Sana Biotechnology Inc's market cap, and MINISO Group Holding Ltd pays a 7.34% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold MINISO Group Holding Ltd for 25 Days and Sana Biotechnology Inc for 23 Days on average.
| MNSO | SANA | |
|---|---|---|
Market Cap | $2.65B | $836.71M |
Volume | 747,763 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.75 | $5.92 |
52-Week Low | $8.60 | $2.68 |
Typical Hold Time | 25 Days | 23 Days |
Enterprise Value | $3.52B | $749.96M |
Dividend Yield | 7.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $9.07, up 1.45% with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company reported strong revenue growth to $21.44B in 2025 with 5.35% net margin, though recent quarterly earnings show volatility with three misses and one beat. Valuation appears reasonable with P/E of 14.76 and P/S of 0.79. Recent CFO share purchases and positive domestic performance provide support amid overseas margin pressures.
The stock presents a value opportunity with attractive valuation multiples and solid Chinese market growth, but faces execution risks from international expansion and earnings inconsistency. Analyst consensus leans bullish (60% buy ratings) despite recent price weakness, suggesting potential upside if management can stabilize overseas operations and maintain domestic momentum.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
